Sinopharm Tech Holdings Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	1.6yrs

Recent management updates

Recent updates

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Feb 02

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 29

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

Nov 24

CEO

Sinopharm Tech Holdings has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kam Kin Ho	Compliance Officer	1.6yrs	HK$1.47m	no data
Shuk Yi Kwok	Director of Group Human Resources & Administration and Executive Director	1.6yrs	HK$1.00m	no data
Pik Lun Heung	Independent Non-Executive Director	less than a year	no data	no data
Fai Lau	Independent Non-Executive Director	4.3yrs	HK$104.00k	no data
Yanjie Cheng	Non-Executive Director	4.8yrs	HK$104.00k	0.043% HK$ 7.9k
Dong An Hsu	Independent Non-Executive Director	less than a year	no data	no data

1.6yrs

Average Tenure

49.5yo

Average Age

Experienced Board: 8156's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Sinopharm Tech Holdings Management

Management criteria checks 0/4

Key information

Recent management updates

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023

Sinopharm Tech Holdings Limited Appoints HEUNG Pik Lun as an Independent Non-Executive Director and A Member of the Audit Committee and the Nomination Committee

Sinopharm Tech Holdings Limited Announces the Resignation of LAM Kit Sun as Independent Non-Executive Director, Member of the Audit Committee and the Remuneration Committee and the Chairperson and Member of the Nomination Committee

Less than half of directors are independent

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 16, 2022

Recent updates

Second quarter 2024 earnings released: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)

Sinopharm Tech Holdings Limited to Report First Half, 2024 Results on Feb 29, 2024

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023

First quarter 2024 earnings released: HK$0.013 loss per share (vs HK$0.024 profit in 1Q 2023)

Sinopharm Tech Holdings Limited to Report Q1, 2024 Results on Nov 14, 2023

Full year 2023 earnings released: HK$0.001 loss per share (vs HK$0.49 loss in FY 2022)

Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023

Sinopharm Tech Holdings Limited to Report Fiscal Year 2023 Results on Sep 29, 2023

Sinopharm Tech Holdings Limited Appoints HEUNG Pik Lun as an Independent Non-Executive Director and A Member of the Audit Committee and the Nomination Committee

New major risk - Share price stability

Third quarter 2023 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 3Q 2022)

Sinopharm Tech Holdings Limited Announces the Resignation of LAM Kit Sun as Independent Non-Executive Director, Member of the Audit Committee and the Remuneration Committee and the Chairperson and Member of the Nomination Committee

Second quarter 2023 earnings released: EPS: HK$0.002 (vs HK$0.001 loss in 2Q 2022)

Sinopharm Tech Holdings Provides Earnings Guidance for the Six Months Ended December 31, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: EPS: HK$0.001 (vs HK$0.002 loss in 1Q 2022)

Less than half of directors are independent

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 16, 2022

Sinopharm Tech Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended 30 September 2022

Sinopharm Tech Holdings Limited to Report Q1, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: HK$0.02 loss per share (vs HK$0.025 loss in FY 2021)

Sinopharm Tech Holdings Limited to Report Fiscal Year 2022 Results on Sep 30, 2022

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited Announces Management Changes

Chan Ting Resigns as CEO of Sinopharm Tech Holdings Limited

Third quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.004 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

First quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.001 loss in 1Q 2021)

Full year 2021 earnings released: HK$0.025 loss per share (vs HK$0.039 loss in FY 2020)

Insider recently bought HK$15m worth of stock

Co-Founder & Non-Executive Director Tung Mei Chan has left the company

Third quarter 2021 earnings released: HK$0.004 loss per share (vs HK$0.004 loss in 3Q 2020)

Sinopharm Tech Holdings Limited (SEHK:8156) entered into a sale and purchase agreement to acquire 25% stake in Shenzhen Ficus Technology Holdings Ltd. from Sharp Associates Limited for HKD 200 million.

New 90-day high: HK$0.29

Second quarter 2021 earnings released: HK$0.002 loss per share (vs HK$0.003 loss in 2Q 2020)

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Sinopharm Tech Holdings Limited to Report First Half, 2021 Results on Feb 10, 2021

Sinopharm Tech Holdings Limited Announces Board Changes

New 90-day high: HK$0.22

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: HK$0.20

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

First quarter 2021 earnings released: HK$0.001 loss per share

Sinopharm Tech Holdings Limited to Report Q1, 2021 Results on Nov 12, 2020

Full year earnings released - HK$0.039 loss per share

Sinopharm Tech Holdings Limited(SEHK:8156) dropped from S&P Global BMI Index

Sinopharm Tech Holdings Limited to Report Fiscal Year 2020 Results on Sep 29, 2020

CEO

Board Members

Average Tenure

Average Age